Where Does VKTX Stock Stand After the Obesity Pill Setback?

Key Takeaways Viking's oral obesity pill VK2735 cut weight but showed high dropout rates due to side effects.Investors worry oral safety issues could affect VKTX's SC version now in late-stage development.VKTX trades at a premium valuation, with widening 2025 and 2026 loss per share estimates.Viking Therapeutics (VKTX) is one of the few biotech stocks that has shown immense potential in this space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in multiple clinical st ...